Compares inflammation markers in people with and without bowel disease
Studies inflammation markers in people with inflammatory bowel disease and control participants.
Plain-language title generated from the registry record
Registry title: NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study
Key facts
- Where
- Nottingham, United KingdomSee the site
Where in United Kingdom
- University of NottinghamNottingham, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Nottingham
- Trial code
- NCT06956703
- Record updated
- 8 July 2026
- Original description
The goal of this observational study is to learn about the comparisons of inflammatory markers between IBD and non-IBD (control) participants.Read full original descriptionShow less
NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study
The goal of this observational study is to learn about the comparisons of inflammatory markers between IBD and non-IBD (control) participants.
The main question it aims to answer is:
Are there differences in inflammatory markers between IBD and non-IBD (control) participants.
Inclusion: Provision of signed and dated, written informed consent before any study specific procedures; AND; 2a. Patients of at least 16 years of age with active Crohn's disease defined as: CRP > = 5 mg/L OR FCP > = 250 μg/g OR Visible ulcerations on ileocolonoscopy with a total SES-CD > = 7, or > = 4 if disease is confined to the terminal ileum OR visable active disease on cross-sectional imaging. Are switching to a new mechanism of action (MOA) onto anti-TNF therapy or ustekinumab or upadacitinib; OR; 2b. Patients of at least 16 years (no upper age limit) with active UC defined as: CRP > = 5 mg/L OR FCP > = 250 μg/g OR Mayo endoscopy subscore > = 2. Are switching to a new mechanism of action (MOA) onto either anti-TNFα therapy or vedolizumab; OR; 2c. Non-IBD participants who are attending for a lower GI colonoscopy at any participating site. On any hospital/ medical/ clinical screening list or any other appropriate list with no pathology found on examination.
Exclusion: Participation in a clinical study with pharmacological intervention within 3 months prior to Baseline visit; Having received a solid organ or stem cell transplant; For non-IBD participants: A prior history of IBD (CD, UC, microscopic colitis, indeterminate colitis or IBD unspecified); An ongoing infection requiring treatment; Clinical evidence of active COVID infection and/or evidence of active COVID determined by local standard care procedures; Current diagnosis of cancer; Any positive result from previous screening for serum hepatitis B surface antigen, hepatitis C or human immunodeficiency virus (HIV); Having received a transfusion of blood, plasma, or platelets within 120 days prior to enrolment; Under 16yrs of age; Inability to give informed consent; Confirmed pregnancy at time of enrolment; Clinical judgement by the investigator that the patient should not participate in the study.